| Drug Name |
Etoricoxib |
| Drug ID |
BADD_D00856 |
| Description |
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US. |
| Indications and Usage |
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. |
| Marketing Status |
approved; investigational |
| ATC Code |
M01AH05 |
| DrugBank ID |
DB01628
|
| KEGG ID |
D03710
|
| MeSH ID |
D000077613
|
| PubChem ID |
123619
|
| TTD Drug ID |
D09MGR
|
| NDC Product Code |
42765-006; 68554-0053 |
| UNII |
WRX4NFY03R
|
| Synonyms |
Etoricoxib | MK 0663 | MK-0663 | MK0663 | Arcoxia | L-791456 | L 791456 | L791456 |
